Inquire Before Buying
Speak to an Analyst 
Request Brochure 
Request CustomizationIMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
Read More
Hypoactive Sexual Desire Disorder Treatment Market Report by Therapy (Buspirone, Bupropion, Testosterone, Flibanserin, Bremelanotide, Cognitive Behavior Therapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Application (Hospitals, Clinics, and Others), and Region 2024-2032
Report Format: PDF+Excel | Report ID: SR112024A2780
Buy Now
Market Overview:
The global hypoactive sexual desire disorder treatment market size reached US$ 2.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.7 Billion by 2032, exhibiting a growth rate (CAGR) of 4.52% during 2024-2032.
|
Report Attribute
|
Key Statistics
|
|---|---|
|
Base Year
|
2023
|
|
Forecast Years
|
2024-2032
|
|
Historical Years
|
2018-2023
|
|
Market Size in 2023
|
US$ 2.5 Billion |
|
Market Forecast in 2032
|
US$ 3.7 Billion |
| Market Growth Rate 2024-2032 | 4.52% |
Hypoactive sexual desire disorder (HSDD) refers to a medical condition with low libido or sexual desire in women. The sexual dysfunction in HSDD is primarily associated with hyperfunction inhibition and hypofunctional excitation regulated by neuromodulators in the brain. Furthermore, several physical conditions are also related to HSDD, including anxiety, depression, diabetes, urinary incontinence, menopause, multiple sclerosis, etc. HSDD treatment mainly includes psychotherapy or pharmacotherapy. Psychotherapy utilizes cognitive behavioral therapy, which offers counseling sessions with a sex therapist, whereas pharmacotherapy comprises of treatment with several drugs, such as Buspirone, Bupropion, Testosterone, Flibanserin, etc.
The rising working women population coupled with their hectic work schedules often result in low libido conditions, thereby augmenting the demand for HSDD treatment. Furthermore, the high prevalence of numerous lifestyle ailments, such as anxiety, stress, depression, prolonged fatigue, irregular menstruation, etc., is also catalyzing the incidences of HSDD. Additionally, diminished libido can also be a side-effect of certain chemical-based drugs that may further lead imbalance of neurotransmitters in the brain, causing HSDD. Moreover, the rising aging women population, premature menopause, and low self-esteem towards one’s physical appearance is also associated with low libido in women, thereby driving the demand for HSDD treatment. Besides this, the reducing stigma associated with HSDD coupled with the growing awareness towards the disease diagnosis and effective treatment is further propelling the market growth. The emergence of the PLISSIT model (Permission, Limited Information, Specific Suggestions, and Intensive Therapy) aids in the initial screening of HSDD. Furthermore, the faster drug approvals for treating HSDD along with the increasing investments in new drug development activities are further catalyzing the market growth. For instance, the U.S. Food and Drug Administration (FDA) approved ‘Vyleesi’ that activates melanocortin receptors for improving sexual desire in women.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hypoactive sexual desire disorder treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on therapy, distribution channel and application.
Breakup by Therapy:
- Buspirone
- Bupropion
- Testosterone
- Flibanserin
- Bremelanotide
- Cognitive Behavior Therapy
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Breakup by Application:
- Hospitals
- Clinics
- Others
Breakup by Region:
- North America
- United States
- Canada
- Europe
- United Kingdom
- Germany
- France
- Spain
- Italy
- Russia
- Others
- Asia Pacific
- China
- Japan
- India
- South Korea
- Others
- Middle East and Africa
- Saudi Arabia
- Iran
- Turkey
- Others
- Latin America
- Brazil
- Mexico
- Others
Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Allergan Plc, AMAG Pharmaceuticals, Inc., Emotional Brain BV, Endoceutics, Inc., GlaxoSmithKline Plc, Ovoca Bio Plc, Pivot Pharmaceuticals, Inc., Palatin Technologies, Inc., S1 Biopharma, Inc., and Sprout Pharmaceuticals, Inc.
Report Coverage:
| Report Features | Details |
|---|---|
| Base Year of the Analysis | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Units | US$ Billion |
| Segment Coverage | Therapy, Distribution Channel, Application, Region |
| Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Countries Covered | United States, Canada, United Kingdom, Germany, France, Spain, Italy, Russia, China, Japan, India, South Korea, Saudi Arabia, Iran, Turkey, Brazil, Mexico |
| Companies Covered | Allergan Plc, AMAG Pharmaceuticals, Inc., Emotional Brain BV, Endoceutics, Inc., GlaxoSmithKline Plc, Ovoca Bio Plc, Pivot Pharmaceuticals, Inc., Palatin Technologies, Inc., S1 Biopharma, Inc., and Sprout Pharmaceuticals, Inc. |
| Customization Scope | 10% Free Customization |
| Report Price and Purchase Option | Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899 |
| Post-Sale Analyst Support | 10-12 Weeks |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global hypoactive sexual desire disorder treatment market was valued at US$ 2.5 Billion in 2023.
We expect the global hypoactive sexual desire disorder treatment market to exhibit a CAGR of 4.52% during 2024-2032.
The rising prevalence of Hypoactive Sexual Desire Disorder (HSDD), along with the increasing focus on R&D of new drugs and therapies for more effective treatment of HSDD, is primarily driving the global hypoactive sexual desire disorder treatment market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective treatment procedures for HSDD to reduce the risk of the coronavirus infection upon hospital visits and interaction with healthcare professionals or medical equipment.
Based on the therapy, the global hypoactive sexual desire disorder treatment market can be segmented into buspirone, bupropion, testosterone, flibanserin, bremelanotide, and cognitive behavior therapy. Currently, bupropion holds the majority of the total market share.
Based on the distribution channel, the global hypoactive sexual desire disorder treatment market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, hospital pharmacies currently exhibit a clear dominance in the market.
Based on the application, the global hypoactive sexual desire disorder treatment market can be categorized into hospitals, clinics, and others. Currently, hospitals account for the largest market share.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global hypoactive sexual desire disorder treatment market include Allergan Plc, AMAG Pharmaceuticals, Inc., Emotional Brain BV, Endoceutics, Inc., GlaxoSmithKline Plc, Ovoca Bio Plc, Pivot Pharmaceuticals, Inc., Palatin Technologies, Inc., S1 Biopharma, Inc., and Sprout Pharmaceuticals, Inc.
Need more help?
- Speak to our experienced analysts for insights on the current market scenarios.
- Include additional segments and countries to customize the report as per your requirement.
- Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
- For further assistance, please connect with our analysts.
Purchase options
Benefits of Customization
Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-631-791-1145
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-713-2163
Email: sales@imarcgroup.com
Client Testimonials
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
Read More
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
Read More
Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.
Read More.webp)
We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.
Read More
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
Read More
The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.
Read More
My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.
Read More
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
Read More.webp){kind=logo}
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.
Read More
IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.
Read More